SEGMENT REPORTING (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	$ 33,430	$ 28,034	$ 90,541	$ 74,838
Operating Income	4,492	2,142	10,018	4,992
Income before income taxes	4,478	2,211	10,103	4,887
Capital expenditures	758	1,040	2,126	1,976
Depreciation and amortization	1,208	1,166	3,418	3,240
Assets	124,312		124,312		$ 109,719
Net Assets	79,791		79,791		63,528
United States
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	30,845	26,847	84,998	71,170
Assets	121,175		121,175		106,780
Europe
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	1,365	537	2,801	1,598
Assets	3,137		3,137		2,939
Other International
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	1,220	650	2,742	2,070
Operating Segments | Core Companion Animal Health
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	26,386	20,983	74,284	61,312
Operating Income	2,995	697	7,499	2,768
Income before income taxes	2,994	782	7,526	2,703
Capital expenditures	202	228	681	677
Depreciation and amortization	996	988	2,807	2,712
Assets	104,363		104,363		92,567
Net Assets	61,951		61,951		48,175
Operating Segments | Other Vaccines, Pharmaceuticals and Products
Segment Reporting, Other Significant Reconciling Item [Line Items]
Total revenue	7,044	7,051	16,257	13,526
Operating Income	1,497	1,445	2,519	2,224
Income before income taxes	1,484	1,429	2,577	2,184
Capital expenditures	556	812	1,445	1,299
Depreciation and amortization	212	$ 178	611	$ 528
Assets	19,949		19,949		17,152
Net Assets	$ 17,840		$ 17,840		$ 15,353